Genprex Decides To Cease Enrollment In The Acclaim-2 Clinical Trial Due To Difficulties In Recruiting Patients, Citing Competition From Numerous Other Trials.; Limiting The Acclaim-1 Trial To A Single Cohort Due To Resource Prioritization, Reducing...

由於招募患者遇到諸多與其他許多臨床試驗的競爭，genprex決定停止在Acclaim-2臨床試驗中招募患者。出於資源優先考慮，將Acclaim-1試驗限制爲單個隊列，從而減少了試驗規模...

Benzinga · 08/14 21:46

Genprex Decides To Cease Enrollment In The Acclaim-2 Clinical Trial Due To Difficulties In Recruiting Patients, Citing Competition From Numerous Other Trials.; Limiting The Acclaim-1 Trial To A Single Cohort Due To Resource Prioritization, Reducing The Potential Breadth Of The Study

Genprex決定停止Acclaim-2臨床試驗的招募，原因是招募患者存在困難，競爭對手衆多。由於資源優先考慮，將Acclaim-1試驗限制爲單個隊列，從而降低了該研究的潛在廣度

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。